DK2691116T3 - Nanopartikler ladet med kemoterapeutisk antitumorlægemiddel - Google Patents
Nanopartikler ladet med kemoterapeutisk antitumorlægemiddel Download PDFInfo
- Publication number
- DK2691116T3 DK2691116T3 DK12713673.7T DK12713673T DK2691116T3 DK 2691116 T3 DK2691116 T3 DK 2691116T3 DK 12713673 T DK12713673 T DK 12713673T DK 2691116 T3 DK2691116 T3 DK 2691116T3
- Authority
- DK
- Denmark
- Prior art keywords
- doxorubicin
- cancer
- nanoparticules
- nanoparticles
- rats
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Manufacturing & Machinery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Nanopartikler, der omfatter mindst ét kemoterapeutisk antitumormiddel, mindst én poly(alkylcyanoacrylat) og mindst én cyclodextrin, til anvendelse til behandling af cancer, hvor nanopartiklerne administreres ved hjælp af intravenøs eller intraarteriel infusion i mindst 2 timer, hvor det mindst ene kemoterapeutiske antitumormiddel er doxorubicin eller et hvilket som helst farmaceutisk acceptabelt salt deraf, og dosen af doxorubicin er fra ca. 20 til ca. 30 mg/m2.
2. Nanopartikler til anvendelse ifølge krav 1, hvor dosen af doxorubicin er ca. 20 mg/m2.
3. Nanopartikler til anvendelse ifølge krav 1, hvor dosen af doxorubicin er ca. 30 mg/m2.
4. Nanopartikler til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor nanopartiklerne administreres ved hjælp af intravenøs eller intraarteriel infusion i mellem 2 og 24 timer.
5. Nanopartikler til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor nanopartiklerne administreres ved hjælp af intravenøs eller intraarteriel infusion i mellem 4 og 12 timer.
6. Nanopartikler til anvendelse ifølge et hvilket som helst af kravene 1-3, hvor nanopartiklerne administreres ved hjælp af intravenøs eller intraarteriel infusion i ca. 6 timer.
7. Nanopartikler til anvendelse ifølge et hvilket som helst af kravene 1-6, hvor den mindst ene poly(alkylcyanoacrylat) er en polyisohexylcyanoacrylat.
8. Nanopartikler til anvendelse ifølge et hvilket som helst af kravene 1-7, hvor nanopartiklerne omfatter det mindst ene kemoterapeutiske middel ved en koncentration fra 0,01 til 200 mg/g af nanopartiklerne, fra 0,1 til 70 % vægt/vægt af den mindst ene cyclodextrin og fra 1 til 25 % vægt/vægt af den mindst ene poly(alkylcyanoacrylat).
9. Nanopartikler til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor canceren er en fast tumor eller en hæmatopoietisk tumor, der fortrinsvis er udvalgt fra gruppen, der består af hepatocellulært karcinom, akut lymfoblastisk leukæmi, akut myeloblastisk leukæmi, kronisk myelogen leukæmi, Hodgkins sygdom, diffust storcellet B-celle-lymfom, småcellet lungecancer, kolorektal cancer, pankreascancer, brystcancer, ovariecancer, uteruscancer, cervixcancer, hoved- og halscancer, hjernecancer, blærecancer, multipelt myelom, neuroblastom, Edwings sarkom, osteosarkom, bløddelssarkom, thyreoideacancer, prostatacancer, mavecancer, nefroblastom, Kaposis sarkom og non-Hodgkins lymfom.
10. Nanopartikler til anvendelse ifølge et hvilket som helst af kravene 1-8, hvor canceren er et hepatocellulært karcinom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11305364.9A EP2508207B1 (en) | 2011-03-31 | 2011-03-31 | Nanoparticles loaded with chemotherapeutic antitumoral Drug |
| PCT/EP2012/055756 WO2012131018A1 (en) | 2011-03-31 | 2012-03-30 | Nanoparticles loaded with chemotherapeutic antitumoral drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2691116T3 true DK2691116T3 (da) | 2016-07-04 |
Family
ID=44513370
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11305364.9T DK2508207T3 (da) | 2011-03-31 | 2011-03-31 | Nanopartikler ladet med kemoterapeutisk antitumormiddel |
| DK12713673.7T DK2691116T3 (da) | 2011-03-31 | 2012-03-30 | Nanopartikler ladet med kemoterapeutisk antitumorlægemiddel |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11305364.9T DK2508207T3 (da) | 2011-03-31 | 2011-03-31 | Nanopartikler ladet med kemoterapeutisk antitumormiddel |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9763874B2 (da) |
| EP (2) | EP2508207B1 (da) |
| JP (1) | JP5523638B2 (da) |
| KR (1) | KR101578273B1 (da) |
| CN (2) | CN105233301A (da) |
| AU (1) | AU2012233666B2 (da) |
| BR (1) | BR112013019105A2 (da) |
| CA (1) | CA2822177C (da) |
| CY (1) | CY1117868T1 (da) |
| DK (2) | DK2508207T3 (da) |
| ES (2) | ES2424476T3 (da) |
| HK (1) | HK1192841A1 (da) |
| HR (2) | HRP20130702T1 (da) |
| HU (1) | HUE028465T2 (da) |
| IL (1) | IL227466A (da) |
| ME (1) | ME02470B (da) |
| MX (1) | MX344704B (da) |
| MY (1) | MY162339A (da) |
| PL (1) | PL2508207T3 (da) |
| PT (1) | PT2508207E (da) |
| RS (1) | RS52880B (da) |
| RU (1) | RU2616494C2 (da) |
| SG (1) | SG193453A1 (da) |
| SI (1) | SI2691116T1 (da) |
| SM (1) | SMT201600197B (da) |
| WO (1) | WO2012131018A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2508207T3 (pl) | 2011-03-31 | 2013-09-30 | Bioalliance Pharma | Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy |
| BR112014031471B1 (pt) * | 2012-07-17 | 2020-12-01 | Dow Global Technologies Llc | composição líquida, uso da composição líquida, dispersão sólida, processo para produzir a dispersão sólida e processo para revestir uma forma de dosagem |
| ES2818110T3 (es) | 2014-02-28 | 2021-04-09 | Merck Sharp & Dohme | Tratamiento del cáncer con una combinación que comprende dinaciclib |
| US20170151181A1 (en) * | 2014-04-18 | 2017-06-01 | Pfizer Inc. | Methods of treating cancers with therapeutic nanoparticles |
| US10092550B2 (en) | 2014-10-21 | 2018-10-09 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing curcumin, harmine, and isovanillin components, and methods of use thereof |
| US20160106722A1 (en) | 2014-10-21 | 2016-04-21 | Life Plus, LLC | Human therapeutic agents |
| US9907786B2 (en) | 2014-10-21 | 2018-03-06 | Ions Pharmaceutical S.À R.L. | Therapeutic compositions containing harmine and isovanillin components, and methods of use thereof |
| AU2016298210B2 (en) | 2015-07-28 | 2021-12-09 | Board Of Regents, The University Of Texas System | Implant compositions for the unidirectional delivery of therapeutic compounds to the brain |
| WO2017046037A1 (en) | 2015-09-14 | 2017-03-23 | Onxeo | Nanoparticles loaded with active ingredients, their process of preparation and their uses |
| CA3015241A1 (en) * | 2016-02-22 | 2017-08-31 | Onxeo | Combination therapies comprising immuno-oncology agents and belinostat |
| NO342271B1 (en) * | 2016-09-29 | 2018-04-30 | Sintef Tto As | A new drug delivery system for treatment of cancer |
| US10646540B2 (en) | 2016-11-18 | 2020-05-12 | City Of Hope | Peptide inhibitors of twist |
| CN106511365A (zh) * | 2016-12-17 | 2017-03-22 | 郑州郑先医药科技有限公司 | 一种治疗肝硬化的西药组合物 |
| JP7317038B2 (ja) * | 2018-03-27 | 2023-07-28 | シンテフ ティーティーオー エイエス | がん治療に使用するためのポリ（アルキルシアノアクリレート）ナノ粒子 |
| MX2019015508A (es) | 2019-12-18 | 2021-06-21 | Univ Guadalajara | Nanopartículas para el tratamiento del cáncer. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4310667A (en) | 1976-04-22 | 1982-01-12 | Agence Nationale De Valorisation De La Recherche (Anvar) | 2-N Quaternary ammonium salt derivatives of 9-hydroxy ellipticine |
| FR2775435B1 (fr) * | 1998-02-27 | 2000-05-26 | Bioalliance Pharma | Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs |
| IL165392A0 (en) * | 2002-06-05 | 2006-01-15 | Genentech Inc | Compositions and methods for liver growth and liver protection |
| US20040202665A1 (en) * | 2002-07-01 | 2004-10-14 | Janette Lazarovits | Compositions and methods for therapeutic treatment |
| JP5201763B2 (ja) * | 2007-02-28 | 2013-06-05 | 昇一 城武 | 異なる平均粒径サイズの粒子からなる混合微粒子カプセルの製造方法 |
| US20090061009A1 (en) * | 2007-08-29 | 2009-03-05 | Joseph Schwarz | Composition and Method of Treatment of Bacterial Infections |
| EP2050747A1 (en) | 2007-10-12 | 2009-04-22 | BioAlliance Pharma | Dimers of harmol or of its derivatives and uses thereof |
| AU2008315718A1 (en) * | 2007-10-26 | 2009-04-30 | Pfizer Products Inc. | Idarubicin for the treatment of lymphoma in a dog |
| WO2009108932A2 (en) * | 2008-02-28 | 2009-09-03 | The Johns Hopkins University | Selectin ligands useful in the diagnosis and treatment of cancer |
| EP2153821A1 (en) * | 2008-08-06 | 2010-02-17 | BioAlliance Pharma | Oral formulations of camptothecin derivatives |
| PL2508207T3 (pl) | 2011-03-31 | 2013-09-30 | Bioalliance Pharma | Nanocząsteczki zawierające chemioterapeutyczny lek przeciwnowotworowy |
-
2011
- 2011-03-31 PL PL11305364T patent/PL2508207T3/pl unknown
- 2011-03-31 RS RS20130322A patent/RS52880B/en unknown
- 2011-03-31 ES ES11305364T patent/ES2424476T3/es active Active
- 2011-03-31 EP EP11305364.9A patent/EP2508207B1/en not_active Not-in-force
- 2011-03-31 PT PT113053649T patent/PT2508207E/pt unknown
- 2011-03-31 DK DK11305364.9T patent/DK2508207T3/da active
-
2012
- 2012-03-30 US US14/009,021 patent/US9763874B2/en not_active Expired - Fee Related
- 2012-03-30 CA CA2822177A patent/CA2822177C/en not_active Expired - Fee Related
- 2012-03-30 BR BR112013019105-8A patent/BR112013019105A2/pt not_active Application Discontinuation
- 2012-03-30 SG SG2013069091A patent/SG193453A1/en unknown
- 2012-03-30 KR KR1020137020892A patent/KR101578273B1/ko not_active IP Right Cessation
- 2012-03-30 SI SI201230615A patent/SI2691116T1/sl unknown
- 2012-03-30 RU RU2013128934A patent/RU2616494C2/ru not_active IP Right Cessation
- 2012-03-30 MY MYPI2013003362A patent/MY162339A/en unknown
- 2012-03-30 AU AU2012233666A patent/AU2012233666B2/en not_active Ceased
- 2012-03-30 JP JP2013550917A patent/JP5523638B2/ja not_active Expired - Fee Related
- 2012-03-30 DK DK12713673.7T patent/DK2691116T3/da active
- 2012-03-30 CN CN201510763081.5A patent/CN105233301A/zh active Pending
- 2012-03-30 EP EP12713673.7A patent/EP2691116B8/en active Active
- 2012-03-30 HU HUE12713673A patent/HUE028465T2/en unknown
- 2012-03-30 ME MEP-2016-122A patent/ME02470B/me unknown
- 2012-03-30 ES ES12713673.7T patent/ES2577955T3/es active Active
- 2012-03-30 CN CN2012800092750A patent/CN103379920A/zh active Pending
- 2012-03-30 MX MX2013007581A patent/MX344704B/es active IP Right Grant
- 2012-03-30 WO PCT/EP2012/055756 patent/WO2012131018A1/en active Application Filing
-
2013
- 2013-07-14 IL IL227466A patent/IL227466A/en active IP Right Grant
- 2013-07-24 HR HRP20130702AT patent/HRP20130702T1/hr unknown
-
2014
- 2014-06-18 HK HK14105794.1A patent/HK1192841A1/zh not_active IP Right Cessation
-
2016
- 2016-06-20 HR HRP20160708TT patent/HRP20160708T1/hr unknown
- 2016-06-23 SM SM201600197T patent/SMT201600197B/it unknown
- 2016-06-23 CY CY20161100574T patent/CY1117868T1/el unknown
-
2017
- 2017-08-10 US US15/673,661 patent/US20170333341A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2691116T3 (da) | Nanopartikler ladet med kemoterapeutisk antitumorlægemiddel | |
| KR101943230B1 (ko) | 항암제로서 라파마이신 및 알부민을 포함하는 나노입자 | |
| AU2017246316A1 (en) | Methods for solid tumor treatment | |
| KR20130109025A (ko) | 방광암의 치료 방법 | |
| CN109771663B (zh) | 一种酸响应性抗癌纳米药物的制备及应用 | |
| WO2015187194A1 (en) | Use of paclitaxel particles | |
| CN108495619A (zh) | 棘霉素制剂及其制备方法和使用方法 | |
| KR20180103039A (ko) | 방광암 치료용 제제 | |
| Fu et al. | Transferrin-modified nanoliposome codelivery strategies for enhancing the cancer therapy | |
| Zhu et al. | Multi-targeting liposomal codelivery of cisplatin and rapamycin inhibits pancreatic cancer growth and metastasis through stromal modulation | |
| Miao et al. | Preparation of DOX/BSANP and its antitumor effect on bel-7404 liver cancer cells in vitro and in vivo | |
| TWI719182B (zh) | 奈米組成物、其製造方法及其用途 | |
| WO2013149538A1 (zh) | 药用组合物 | |
| US20170071866A1 (en) | Nanoparticles loaded with active ingredients, their process of preparation, and their uses | |
| WO2017046037A1 (en) | Nanoparticles loaded with active ingredients, their process of preparation and their uses | |
| EP4153180A1 (en) | Combination therapy for treating cancer | |
| JP4020256B2 (ja) | 前立腺癌の局所治療剤 | |
| Chawla et al. | Longer term cardiac safety of aldoxorubicin |